Aptorum Group unveils progress on repurposed drug candidate for neuroblastoma

KUALA LUMPUR, Feb 11 -- Biopharmaceutical company, Aptorum Group Limited (Aptorum Group) has announced positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma.

Neuroblastoma is a rare type of childhood cancer that develops in infants and young children. Subject to completion of current validation studies, Aptorum Group plans to leverage the 505(b)(2) pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.

SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACTTM drug discovery platform using systematic approach to identify, repurpose and develop existing approved drugs against a currently identified universe of over 7,000 (and increasing) orphan diseases.

Via this platform, Aptorum Group intends to accelerate and fast track repurposed drug candidates through the development and clinical phases to address the rapidly growing market of orphan diseases.

Through the Smart-ACTTM platform, Aptorum Group has successfully identified potential efficacy for and develops SACT-1 for the treatment of neuroblastoma, being an entirely new therapeutic area from its approved indication.

In its recent studies, SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which two are MYCN-amplified cells, representing the high-risk neuroblastoma patient group.

The reformulation of SACT-1 is a pediatric formulation to better address the needs of neuroblastoma patients who are exclusively children younger than five.

More details at www.aptorumgroup.com.

-- BERNAMA